BioMarin Pharmaceutical is continuing to slim down its pipeline, this time ending work on a preclinical phenylketonuria (PKU) drug once touted as a potential successor to its approved med Palynziq.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback